James Peyer is the Founder and Managing Partner of Kronos BioVentures, a biotechnology fund investing in breakthrough therapeutics that affect fundamental mechanisms of our natural degeneration we call aging. Kronos founds, invests, and builds biotech companies. He created Kronos to explore the potential of our newfound knowledge of what makes us age, believing that medicines derived from this knowledge will enable the greatest medical breakthroughs of the 21st century.
Before Kronos, James founded and built Apollo Ventures, a life science investment arm of a group of impact-minded family offices in Europe. He built Apollo from its founding to becoming one of the world’s leading investors in longevity biotech. He led investments in Cleara Biotech, Aeonian Pharmaceuticals, and Samsara Therapeutics.
Before Apollo, James worked as a McKinsey consultant, earned his doctorate at UTSW as a National Science Foundation fellow, and got his undergraduate with special honors from the University of Chicago.